

University of Groningen

Nitric Oxide-cGMP Signaling in Hypertension

Ataei Ataabadi, Ehsan; Golshiri, Keivan; Juttner, Annika; Krenning, Guido; Danser, A. H. Jan; Roks, Anton J. M.

Published in:
Hypertension

DOI:
[10.1161/HYPERTENSIONAHA.120.15856](https://doi.org/10.1161/HYPERTENSIONAHA.120.15856)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Ataei Ataabadi, E., Golshiri, K., Juttner, A., Krenning, G., Danser, A. H. J., & Roks, A. J. M. (2020). Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy. *Hypertension*, 76(4), 1055-1068. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15856>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Nitric Oxide-cGMP Signaling in Hypertension

Current and Future Options for Pharmacotherapy

Ehsan Ataei Ataabadi, Keivan Golshiri, Annika Jüttner,
Guido Krenning¹, A.H. Jan Danser, Anton J.M. Roks

Abstract—For the treatment of systemic hypertension, pharmacological intervention in nitric oxide-cyclic guanosine monophosphate signaling is a well-explored but unexploited option. In this review, we present the identified drug targets, including oxidases, mitochondria, soluble guanylyl cyclase, phosphodiesterase 1 and 5, and protein kinase G, important compounds that modulate them, and the current status of (pre)clinical development. The mode of action of these compounds is discussed, and based upon this, the clinical opportunities. We conclude that drugs that directly target the enzymes of the nitric oxide-cyclic guanosine monophosphate cascade are currently the most promising compounds, but that none of these compounds is under investigation as a treatment option for systemic hypertension.

Key Words: hypertension ■ mitochondria ■ nitric oxide ■ oxidoreductase ■ soluble guanylyl cyclase

Hypertension is a major clinical risk factor for cardiovascular disease, the leading cause of disability and death in developed societies.¹ As a consequence, antihypertensive treatment is expected to deliver a major contribution to healthcare. Current treatments are, however, challenged by a lower than expected protective cardiovascular effect.² The currently used antihypertensive drugs either have a diuretic effect through blockade of sodium/chloride transport in the renal tubule or are blocking the vasoconstriction to calcium, epinephrine/nor-epinephrine, angiotensin II or endothelin, or block the formation of these vasoconstrictors. Thus, it is an intriguing concept to stimulate the production of messenger molecules leading to active vasorelaxation, most notably nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling (Figure 1), to decrease total peripheral resistance and blood pressure. Apart from inducing vasorelaxation, NO—cGMP signaling is also known to reduce blood pressure through other mechanisms.³ First, it decreases renin release, which lowers production of the blood pressure increasing hormone angiotensin II. Second, it increases natriuresis through modulation of various sodium transporters, for example, sodium–hydrogen exchanger 3, epithelial sodium channel, and Na-K-Cl cotransporter 2, in the tubules. However, in this review, the focus will be on vascular NO—cGMP signaling. The main source of vascular NO is eNOS (endothelial NO-synthase).⁴ Upon stimulation of G-protein coupled receptors that increase Ca²⁺ in endothelial cells, eNOS is phosphorylated at Ser1177. Subsequently, with tetrahydrobiopterin (BH₄) as co-factor, eNOS monomers form dimers, and electrons donated by NADPH are transferred to the N-terminal catalytic center, which results in the release of the

NO moiety from the amino acid L-arginine.⁵ NO is oxidized to NO₂⁻, and subsequently to NO₃⁻.^{6,7} NO₃⁻ can be reduced back to NO₂⁻ by commensal bacteria in the gastrointestinal tract and by xanthine oxidoreductase.⁷ NO₂⁻, in turn, can be reduced back to NO (Figure 1) by various nitrite reductases under low pH and oxygen levels, representing a possible mechanism for blood pressure lowering during metabolic acidosis. BP is usually increased during acute hypoxia.⁷ Thus, an NO₂⁻-NO₃⁻-NO cycle is created, the role of which in vasodilation and hypertension has recently been extensively reviewed.⁷

NO diffuses to vascular smooth muscle cells (VSMCs) where it binds sGC (soluble guanylyl cyclase). NO-bound sGC produces cGMP, a key regulator of vascular tone. The rise in intracellular cGMP in VSMCs triggers activation of PKG (protein kinase G) and subsequent phosphorylation of VASP (vasodilator-stimulated phosphoprotein) at serine 239. Thereupon, contracted, phosphorylated actin-myosin is dephosphorylated by myosin light chain phosphatase, resulting in relaxation.⁸ PDEs (phosphodiesterases) that degrade cGMP are present in VSMCs to participate in tonus control.⁴ Next to NO—cGMP signaling endothelium-derived eicosanoids are active to cause vasodilation through cyclic adenosine monophosphate (cAMP) release (prostaglandins), or through endothelium-dependent hyperpolarization (EDH) of VSMCs.⁴

In hypertension, NO—cGMP signaling can be reduced as a consequence of decreased bioavailability of NO due to superoxide. More directly in the NO signaling cascade, decreased NO production due to reduced eNOS levels or uncoupling, reduced cGMP production by sGC, decreased PKG activity, and increased

From the Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands (E.A.A., K.G., A.J., A.H.J.D., A.J.M.R.); Sulfateq B.V., Groningen, the Netherlands (G.K.); and Cardiovascular Regenerative Medicine, Department Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands (G.K.).

Correspondence to Anton J.M. Roks, Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Room Ee1418 Erasmus Medical Centre, PO. Box 2040, 3000 CA Rotterdam, the Netherlands. Email a.roks@erasmusmc.nl

(*Hypertension*. 2020;76:1055-1068. DOI: 10.1161/HYPERTENSIONAHA.120.15856.)

© 2020 American Heart Association, Inc.

Hypertension is available at <https://www.ahajournals.org/journal/hyp>

DOI: 10.1161/HYPERTENSIONAHA.120.15856




Figure 1. Overview of the nitric oxide (NO)-cyclic guanosine monophosphate signaling cascade and inhibitory oxidative pathways in the vascular wall. cGMP indicates cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; Lox, lipoxygenase; Nox, NADPH oxidase; Oxphos, oxidative phosphorylation; PDE, phosphodiesterase; Perox, peroxidase; PKG, protein kinase G; sGC, soluble guanylyl cyclase; and SOD, superoxide dismutase.

cGMP metabolism by PDE can occur, as will be addressed in detail below. The current review will focus on intervention in this signaling cascade. The role of oxidative stress will be shortly summarized, with reference to comprehensive review articles.

NO Donors

Various compounds that release NO are available for clinical use. In hypertensive emergencies, SNP (sodium nitroprusside), given intravenously, is used to rapidly decrease blood pressure. Organic nitrates are instead used to relieve angina pectoris. The use of these NO donors for hypertension is limited by their physicochemical properties (short-term efficacy) and the occurrence of tolerance, caused by inhibition of the nitrate bioactivators (aldehyde dehydrogenase for nitroglycerin and pentaerythrityl tetranitrate, and cytochrome p450 for isosorbide-5-mononitrate and isosorbide dinitrate), and pseudotolerance pathways caused by hormonal counterregulation.⁹

NO Signaling in Relation to Risk Factors

On a more chronic term, intervention in risk factors for cardiovascular disease is widely applied and can act, in part, through improvement of NO—cGMP signaling. As reviewed by Daiber et al¹⁰, the classical cardiovascular risk factors hypertension, dyslipidemia, obesity, diabetes mellitus, smoking and aging, but also sex-related factors (menopause, estrogen-use), air pollution, mental stress, sleep disturbance through noise exposure, and alcohol abuse are all associated with diminished vasodilator function in humans.^{10,11} Lifestyle interventions, such as a healthy diet, exercise, weight reduction, and smoking cessation are first-step therapies. For smoking, nicotine delivery systems and vaping products with nicotine, such as e-cigarettes, have been developed in the hope that these would

have less negative effect on health and may aid in cessation of smoking cigarettes. Nevertheless, flavoring products in vaping fluids scavenge NO in cultured endothelial cells, although this does not necessarily translate into decreased vasodilation in vivo.^{12,13} Also, e-cigarette constituents lead to oxidative stress and cell death in cultured endothelial cells, which could lead to lower levels of NO, although the effects of smoking tobacco cigarettes are generally more pronounced.^{14,15} Systolic and diastolic blood pressure have been reported to change differentially during the acute use of e-cigarettes. Tobacco cigarettes generally increase both systolic and diastolic pressure, varying from 1 to 8 mmHg,¹⁶ while e-cigarettes either affect both, or diastolic pressure only (≈ 7 mmHg).¹⁷ In vivo effects of e-cigarettes on endothelial NO—cGMP and the relation to blood pressure have not been studied yet in parallel. However, recent studies demonstrated that flow-mediated dilation and NO bioavailability in the forearm were decreased shortly after vaping, and implicated NOX (NADPH oxidase) 2, an enzyme that decreases NO bioavailability due to superoxide production as a potential cause.^{18,19} In mice, acetylcholine-induced vasodilation is diminished, and reactive oxygen species (ROS) production is increased from 3 days after vaping. This is absent in NOX2 knockout mice, indicating that oxidative stress due to NOX2 activation underlies the vaping-induced endothelial dysfunction.¹⁸ Macitentan, an antagonist for the vasoconstrictor hormone ET-1 (endothelin-1), and bepridil, an activator of the transcription factor Forkhead box O3 that induces antioxidant gene expression, blocked the effect of vaping-induced endothelial dysfunction.¹⁸ Decreased NO availability due to NOX activation, ET-1 and Forkhead box O3 have also been implicated in noise-induced hypertension, with an important role for inflammation.^{11,20} Therefore,

macitentan and bepridil might also be applicable in this condition. With respect to dietary interventions, nitrate (NO_3^-) and nitrite (NO_2^-) may be of benefit (Figure 1). Beet juice combines the presence of antioxidants with a high amount of NO_3^- . NO_3^- is converted to NO_2^- by bacteria in the gastrointestinal tract.⁶ In short-lasting studies, beet juice has shown to lower blood pressure and to enhance vasodilation. Also, supplementation of NO_3^- and NO_2^- exerted antihypertensive effects in various hypertensive rat models and in human hypertension. For further reading on this topic and an overview of clinical trials, we refer to a recent article.²¹

Reduced NO Bioavailability Due to Oxidative Stress and eNOS Uncoupling

Decrease of bioactive NO by superoxide occurs under the formation of peroxynitrite (ONOO^- ; Figure 1).^{22,23} Superoxide can be produced by a number of enzymes, of which NOX, LOX (lipoxygenase), XO (xanthine oxidase), and peroxidase have been explored as drug targets. Inhibition of NOX has received the widest attention.^{23–29} Based on specificity, the existing NOX inhibitors can be subdivided into 3 generations (Figure 2).^{30,31} Only the third-generation compounds are orally available and sufficiently specific to be used in the clinic, although the potentially antihypertensive NOX inhibitor setanaxib did not meet the clinical end point of a reduction in albuminuria in diabetic nephropathy in a phase II study.^{30–33} Several other third-generation NOX inhibitors are now under preclinical investigation, and results in hypertensive models are awaited.^{34,35} Another approach is the induction of a decrease of NOX gene expression. G36 is an orally available compound that reduces NOX1 transcription through antagonism of GPER (G-protein-coupled estrogen receptor). It prevents angiotensin II-induced hypertension and preserves endothelial vasodilation in rats.^{36,37} XO forms NO from nitrite but also produces O_2^- and H_2O_2 as a waste product during purine degradation.³⁸ As such it might not be an optimal drug target to improve NO signaling.³⁹ Classical purinergic XO inhibitors, allopurinol and oxypurinol, originally developed to treat gout, have been reported to improve endothelial function and to reduce blood pressure, but display variable efficacy and cause renal damage.³⁸ The nonpurine-like XO inhibitor febuxostat mildly reduced blood pressure in rats and humans and improved acetylcholine-induced vasodilation in spontaneously hypertensive rats (SHR), but unfortunately, its use resulted in increased cardiovascular mortality in patients with gout and cardiovascular disease.^{40–43} The lipoxygenase 12/15-LOX catalytically consumes NO during metabolism of polyunsaturated fatty acids and produces O_2^- .⁴⁴ LOX inhibition was proposed as a treatment in hypertension, however, LOX (eg, 15-LOX), is also involved in the production of endothelial vasodilator eicosanoids, limiting it as a target to treat hypertension.^{45,46} Myeloperoxidase is released from polymorphonuclear neutrophils and has the capacity to infiltrate endothelial cells. It consumes NO as a substrate during formation of oxidants, for example, HOCl, that in turn oxidizes NO and its precursor L-arginine.^{47–50} Peroxidase inhibition, therefore, would be a way to upregulate NO.

As an alternative to get rid of surplus superoxides and related oxidative substances pharmacological stimulation of genes coding for antioxidant enzymes has been attempted.

Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a major role in expression of antioxidant genes.⁵¹ The Nrf2-activators bardoxolone methyl and its analogs RTA 405 and dh404 have been tested clinically, but after initially showing renoprotection, a recent clinical trial in patients with end-stage diabetic kidney disease with bardoxolone methyl was halted prematurely because it increased blood pressure and heart failure-induced mortality.^{52,53} This may relate to Nrf2-induced upregulation of renin-angiotensin system (RAS) components,⁵⁴ which might have counteracted the RAS-blocking therapy in the enrolled patients.⁵² Therefore, Nrf2-activation does not seem useful in hypertension in patients who are on RAS inhibition, a well-known antihypertensive and cardiac, vascular and renal protective treatment. It is, however, still an open question if higher dosages of RAS-inhibiting drugs might overcome this problem.

Finally, ROS have been reported to affect eNOS directly. Superoxide and peroxynitrite both oxidize BH_4 to BH_2 , which can compete for eNOS binding.⁵ Depletion of BH_4 combined with reduced binding leads to decreased eNOS dimerization and electron transport. This so-called uncoupling of eNOS forces the enzyme to produce superoxide instead of NO, leading to decreased vasodilation and increased inflammation, thereby contributing to hypertension.^{5,55} Both NOX and vascular peroxidase 1 have been implicated in eNOS uncoupling.^{26,56} Evidence indicated that uncoupling of eNOS underlies the hypertension in rodents exposed to either angiotensin II or deoxycorticosterone acetate-salt, and co-factor supplementation has been suggested as a possible remedy.⁵

NO and Mitochondrial Respiration

Mitochondria interact with NO-cGMP signaling in at least 3 ways: (1) mitochondrial superoxide scavenges NO, (2) mitochondrial arginase II competes with eNOS for L-arginine, and (3) NO regulates mitochondrial respiration.

The formation of free radicals like superoxide by mitochondria is due to spillover of electrons in the respiratory chain during the process of oxidative phosphorylation (Figure 3). This makes the respiratory chain a potential drug target. 6-Chromanol-derived SUL (Sulfateq) compounds preserve mitochondrial membrane potential by activating complex I and IV of the chain, thus keeping up ATP production during respiratory chain-disturbing conditions like ischemia, cooling, warming, and metabolic diseases.^{57,58} For instance, SUL-121 diminished diabetes mellitus-induced kidney damage by upregulating SOD2 (superoxide dismutase 2), and the same is true for SUL-109.^{57–59} SOD2 is an enzyme that is involved in conversion of O_2^- into H_2O_2 .^{29,60} H_2O_2 is a mediator of O_2^- signaling and serves as a vasodilator, but, paradoxically, also as a vasoconstrictor and apoptosis inducer, depending on the vessel type.^{29,61,62} Despite the involvement of SOD2, it is not clear whether the protective effect of SUL-121 arises from increased NO availability due to lowered oxidative stress, the beneficial signaling properties of H_2O_2 , or other mechanisms. SUL compounds mimic the gasotransmitter hydrogen sulphide at complex IV,⁶³ creating a hypometabolic state, which should reduce ROS while preserving ATP synthesis (Figure 3). Hydrogen




Figure 2. Overview of 3 generations of Nox (NADPH oxidase) inhibitors in order of specificity (**top**: low specificity; **bottom**: high specificity). No clinical trials are currently being undertaken with these compounds. ROS indicates reactive oxygen species.

sulphide-releasing compounds, for example, GYY4137, improve NO signaling and lower blood pressure in rats,⁶⁴ but the blood pressure effect appears to be K_{ATP} channel activation- rather than cGMP-mediated. As discussed below, H_2O_2 can mediate vasodilation through hyperpolarization, in which potassium channels are involved. Thus, it is well possible that H_2O_2 -mediated vasodilation is an important complementary mechanism for blood pressure reduction induced by SUL compounds. The (R) enantiomer of SUL-121, SUL-150, also lowers blood pressure, but this is at least partly due to its function as an α -adrenergic receptor antagonist.⁶⁵

The antioxidant MitoQ, selectively accumulating in mitochondria, and the SOD2 mimic mitoTEMPO, both exert beneficial effects in hypertensive animals.^{66,67} Yet, none of this has resulted in a clinical follow-up.

Mitochondrial adaptation (Figure 3) involves inner membrane stabilization, fusion (=the joining of mitochondria to restore function) and inhibition of fission (=mitochondrion splitting).⁶⁸ Elamipretide stabilizes cardiolipin, an important component of the mitochondrial inner membrane.⁶⁹ As a consequence, it restored eNOS levels and endothelium-dependent vasodilation in metabolic syndrome models, yet without affecting blood pressure.^{69,70} The fission inhibitor Mdivi-1 has




Figure 3. Interaction of mitochondrial metabolism with vascular nitric oxide (NO) signaling and vasodilation. Four drug categories (rectangular boxes, underlined text) are of potential interest in hypertension. CAC indicates citric acid cycle; eNOS, endothelial NO-synthase; ETC, electron transport chain; PPP, pentose phosphate pathway; ROS, reactive oxygen species; SOD2, superoxide dismutase 2; and SUL, Sulfateq.

been reported to lower blood pressure and to suppress inflammation in SHR.⁷¹

Arginase II synthesizes L-ornithine from L-arginine. L-ornithine is needed for the production of spermidine and L-proline, that contribute to cell division and collagen formation, respectively. In endothelial cells, arginase II is capable of translocating from mitochondria to the cytoplasm. Since this prevents NO formation from L-arginine by eNOS (Figure 3),⁷² it may cause vasoconstriction contributing to hypertension.^{73,74} Arginase II also upregulates mitochondrial $[Ca^{2+}]$ at the cost of cytosolic $[Ca^{2+}]$, thereby lowering eNOS activity.⁷⁵ Thus, arginase II inhibitors would enhance eNOS activity both by increasing L-arginine availability and by upregulating cytosolic $[Ca^{2+}]$. The classical inhibitors *S*-(2-boronoethyl)-L-cysteine, *N*^G-Hydroxy-L-arginine, and 2(S)-amino-6-borono-hexanoic acid are not under clinical development, and newer compounds, for example, cinnamides, are still in their infancy of development.^{76,77}

Finally, NO inhibits the respiratory chain through its binding to the heme group in cytochrome c oxidase (complex IV) and by formation of peroxynitrite due to its reaction with superoxide.⁷⁸ This process involves the incorporation of both mitochondrial NOS and nitrite reductases that generate NO from nitrites into the mitochondria. Although respiratory chain suppression may result in apoptosis in cardiovascular and renal tissue, thus potentially indirectly contributing to hypertension, there are currently no pharmacological strategies to target this mechanism. Importantly, mitochondrial NO does not result in cGMP signaling.

NO and DNA Damage Response-Related Aging and Hypertension

DNA damage in mice that display accelerated aging due to genetic deletion of the DNA repair enzyme ERCC1 (*Ercc1*^{-/-} mice), leads to premature vascular aging and hypertension. This involves reduced NO-cGMP signaling,^{79–82} due to a combination of decreased eNOS expression and phosphorylation at Ser1177, increased ROS and increased PDE 1 and 5

activity.^{79,80} How this intrinsic process of aging prompted by DNA damage leads to decreased eNOS and increased PDE expression remains to be clarified. Interestingly, a well-known antiaging intervention, dietary caloric restriction (a 10%–30% reduction in food intake), not only increased longevity and health in *Ercc1*^{-/-} mice, but also restored NO signaling, possibly via ROS suppression (Figure 1).^{81,82} Unrepaired DNA damage normally results in the recruitment of protective mechanisms, the so-called survival response.⁸³ This includes Nrf2-regulated antioxidant pathways, hypothetically allowing eNOS to keep its coupled NO-producing state as ROS are decreased. However, as discussed, Nrf2-activation also upregulates RAS components.⁵⁴ Nfr2 is already activated in *Ercc1*^{-/-} mice that are fed ad lib, and RAS blockade with losartan could not restore NO—cGMP signaling.⁸¹ Therefore, Nrf2—RAS signaling does not appear to play a role in the decreased NO—cGMP signaling, or in the effect of dietary caloric restriction, in the vasculature of *Ercc1*^{-/-} mice. An alternative pharmacological strategy to improve vascular aging in *Ercc1*^{-/-} mice is PDE inhibition (see below).⁴

Stimulators and Activators of sGC

The recognition that nitrates were not suitable for the chronic treatment of hypertension led to attempts to exploit downstream targets of NO. In VSMCs, NO binds sGC to form cGMP. Importantly, NO binds at the enzyme's heme group, which contains Fe²⁺. O₂⁻ and peroxynitrite oxidize sGC, leading to Fe³⁺ formation and eventually to loss of the heme group, both leading to inactivation of sGC (Figure 4).⁸⁴ On this basis, the discovery of sGC stimulators and activators could overcome dysfunctional sGC signaling.⁸⁴ Stimulators bind sGC directly, allosterically, outside the heme group, augmenting the catalytic activity to form cGMP (Figure 4). This can take place both NO-independently and in synergy with endogenous NO by stabilizing the NO binding to the sGC heme group. Activators also bind and stimulate sGC in an NO-independent manner. They bind the heme-NO binding pocket, and thus, unlike stimulators, activate the oxidized and heme-free form of sGC




Figure 4. sGC consists of heterodimers formed of α and β subunits, the latter containing a ferrous heme nitric oxide (NO) binding site. Binding of NO activates the catalytic part. Oxidation leads to loss of NO binding, which can be substituted by sGC (soluble guanylyl cyclase) activators. sGC Stimulators act through allosteric binding outside the heme group. Adapted from Sandner et al.⁸⁴ cGMP indicates cyclic guanosine monophosphate.

(Figure 4). In summary, stimulators work NO-independently, as well as in an additive manner with NO, and are heme-dependent, while activators work NO-independently, additive with NO, and are heme-independent.

Despite the clear mechanistic distinction of both drug classes, the World Health Organization assigned them the same suffix: ciguates. Partly, this could be due to the limited understanding of the (patho) physiological role of oxidized and heme-free sGC, in particular of the spatio-temporal pattern of the underlying oxidative stress—which might be variable in different diseases and disease causes. This makes it difficult to predict the treatment potential and efficacy of sGC stimulators and activators. In addition, it is not known if activators and stimulators have a differential efficacy with respect to their treatment effects; head-to-head comparisons have not been made for their diverse applications, and the first oral activators have just reached phase 2 studies. The Table summarizes important cardiovascular applications of these drugs.

Preclinical Data With sGC Stimulators and Activators

The sGC stimulators and activators BAY 41-8543, BAY 58-2667 (cinaciguat), HMR-1766, and YC-1 increase cGMP and relax blood vessels from different animal species.^{85–88} sGC stimulators also relax aortas from nitrate-tolerant rats.⁸⁵ In addition, relaxation of coronary arteries, without any effect

on left ventricular pressure and heart rate, was demonstrated for these drugs in the Langendorff preparation. Increase of coronary blood flow was reported for the sGC stimulators riociguat (BAY 63-2521) and vericiguat (BAY 1021189).^{89,90}

The relaxation of blood vessels induced by sGC stimulators and activators translates into blood pressure decreases in a broad range of animal models including dogs, normotensive rats, and hypertensive rats (SHR and chemically and genetically induced models).^{89–95} It is important to note that the effects of sGC stimulators in these preclinical models were dose-dependent, and that there was no tachyphylaxis, thus avoiding the tolerance problems seen for nitrates.^{89,95} These drugs additionally induced cardiac and vascular antifibrotic effects, offered renal protection, and decreased mortality in stroke-prone SHR rats, and rat models of cardiovascular diseases including models with a hypertensive, diabetic, or metabolic disease background, implying a role in heart failure but also other cardiovascular diseases.^{96–101} In line with that, praliciguat showed efficacy in a rat cardiorenal model of heart failure with reduced ejection fraction.⁹³

Clinical Data With sGC Stimulators and Activators

The only drug registered up to now is the sGC stimulator (riociguat, Adempas). It is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic

Table. Selection of Frequently Used sGC Stimulators and sGC Activators and Their Actual Development Status

	International Nonproprietary Name	Indication(s)/ Highest Development Level	Status
sGC stimulators			
BAY 41-8543	Unknown	Vasorelaxation, also in nitrate-tolerant conditions. Increases coronary perfusion and reduces coronary perfusion pressure in rat. ^{88,95}	Preclinical tool
BAY 41-2272	Unknown	Vasorelaxation and blood pressure decrease in SHR. ¹³⁴	Preclinical tool
YC-1	Lifciguat	Vasorelaxation in normotensive and hypertensive models. ^{86,87}	Preclinical tool
BAY 60-4552	Nelociguat	ED/Phase 2 ¹³⁵	Completed
BAY 63-2521	Riociguat	Blood pressure reduction ⁸⁹ ; PAH/phase 3 ¹³⁶ ; CTEPH/phase 3. ¹³⁷	Completed, approved, marketed as Adempas
BAY 102-1189	Vericiguat	Chronic heart failure (HFrEF)/phase 3. ¹⁰²	Completed
		Chronic heart failure (HFpEF)/phase 2 b, tolerability. ¹³⁸	
IW-1973	Praliguat	Blood pressure-lowering in hypertensive and diabetic nephropathy models, and hypertensive humans. ^{93,106,107,139}	Preclinical tool
		Chronic heart failure (HFpEF)/phase 2. ¹⁴⁰	Ongoing
sGC activators			
HMR-1766	Ataciguat	PAD/phase 2. ¹⁴¹	Completed
BAY 58-2667	Cinaciguat	ADHF/phase 2. ^{103,104}	Completed
BAY 60-2770	Unknown	Vasorelaxation pulmonary hypertension model. ^{142,143}	Preclinical tool
BI 704704	Unknown	Blood pressure lowering and renal protection in ZSF1 rats with diabetic nephropathy. ¹⁴³	Preclinical tool

ADHF indicates acute decompensated heart failure; CTEPH, chronic thromboembolic pulmonary hypertension; ED, erectile dysfunction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; PAD, peripheral arterial occlusive disease; PAH, pulmonary arterial hypertension; sGC, soluble guanylyl cyclase; SHR, spontaneously hypertensive rat; and ZSF1, is a cross between a female Zucker Diabetic Fatty rat and a male Spontaneously Hypertension Heart Failure rat.

pulmonary hypertension. A recent study with vericiguat in patient with heart failure and reduced ejection fraction showed a reduced incidence of death from cardiovascular causes or hospitalization for heart failure versus placebo.¹⁰² The difference favoring vericiguat appeared already after 3 months of treatment. Symptomatic hypotension was more common in the vericiguat group ($P=0.12$). Early studies in acute decompensated heart failure patients with the sGC activator cinaciguat also demonstrated a pronounced blood pressure-lowering effect.^{103–105} Although this led to a premature stop of a trial with cinaciguat, these data support the potential usefulness of ciguats in hypertension.

Phase 1 studies in healthy subjects recently revealed the potential of praliguat as a blood pressure-lowering agent.¹⁰⁶ In a subsequent phase, 2A clinical trial study in hypertensive patients with type 2 diabetes mellitus praliguat lowered 24 hour mean arterial pressure by 5 mmHg, with a greater effect in those with a baseline mean arterial pressure >92 mmHg.¹⁰⁷ Further clinical trials in a broad range of patients with hypertension still have to be performed. Despite the preclinical evidence and the clinical results, currently, no sGC stimulator and sGC activator is in development for the treatment of hypertension. This is at a first glance surprising, since the mode of action

of sGC stimulators and sGC activators is completely different from and complementary to approved antihypertensive drugs.

PDE Inhibitors

PDEs inactivate the second messengers cGMP and cAMP. This large group of enzymes consists of 11 distinctive families or subtypes.⁴ The PDE1-3 and PDE10-11 families are dual-substrate PDEs, that is, they are able to hydrolyze both cAMP and cGMP, while PDE4, -7 and -8 are cAMP-specific and PDE5, -6, and -9 are cGMP-specific. PDEs display a specific tissue distribution which is family- and subtype-dependent. PDEs in VSMC are logical targets for the treatment of hypertension.¹⁰⁸ Here the 2 most abundant cGMP-hydrolyzing PDEs are PDE1, which is Ca^{2+} -calmodulin-dependent, and PDE5 (Figure 5). PDE1 has 3 subtypes A, B, and C, and among them, PDE1A and PDE1B prefer cGMP over cAMP.¹⁰⁹ The relative importance of PDE1 and 5 depends on the (patho) physiological conditions, that is, in VSMC of the quiescent, contractile phenotype and (healthy) conditions featured by relatively low $[Ca^{2+}]$ PDE5 is commanding, while PDE1 presumably has a dominant role under disease conditions, such as in high $[Ca^{2+}]$ conditions and in proliferative VSMC (Figure 5).^{110,111} Thus




Figure 5. PDE (phosphodiesterase) and PKG (protein kinase G) signaling in vascular smooth muscle. Drug classes that decrease blood pressure through these pathways are in boxes and underlined. cGMP indicates cyclic guanosine monophosphate; IDO, indoleamine 2,3-dioxygenase 1; LZ, leucine zipper; S-S, disulfide bridge; and VASP, vasodilator-stimulated phosphoprotein.

PDE1 and PDE5 represent 2 distinct drug targets, and their inhibition has been tested in various models.

Laursen et al¹⁰⁹ evaluated the vasodilatory and blood pressure-lowering effect of 2 PDE1 selective inhibitors (Lu AF41228 and Lu AF58027) in Wistar rats. Both compounds reduced blood pressure within 60 minutes upon intravenous infusion in anesthetized rats, while Lu AF41228 also decreased blood pressure when given orally to conscious animals. PDE1A, PDE1B, and PDE1C mRNA was found in aorta, lung, heart, and brain, while mesenteric small arteries only showed PDE1A and PDE1B mRNA. Mesenteric arteries relaxed dose-dependently to Lu AF41228 and Lu AF58027, and this effect disappeared after endothelium removal or during blockade of eNOS with N^w-Nitro-L-arginine methyl ester HCl. PDE1A null mice display low blood pressure, further supporting the possible role of PDE1 inhibition in blood pressure reduction.¹¹² The PDE1 inhibitor ITI-214 is in clinical development in patients with neurodegenerative disease and heart failure (www.intracellulartherapies.com). No long-term blood pressure studies have been performed in animals, nor have blood pressure effects been reported in humans thus far.

PDE5 inhibitors have been extensively used in clinical conditions, most notably erectile dysfunction (sildenafil) and pulmonary hypertension (sildenafil, vardenafil, and tadalafil). Short-term PDE5 inhibitor treatment (bolus injection or up to 1 week intake) induced mild vasodilator effects in healthy volunteers and a small additive blood pressure-lowering effect in patients already taking other antihypertensive drugs.^{108,113,114} The modesty of this effect might have various causes. First, the other antihypertensive drugs (in particular RAS inhibitors) may already have upregulated the NO pathway. In addition, angiotensin II is capable of upregulating PDE1 and 5,

for example, in resistance arteries.^{115–117} This implies that RAS blockade would lower PDEs, thus reducing the potential efficacy of PDE inhibition. Unfortunately, the blood pressure-lowering effect of PDE5 inhibition seems to wane off over time. For instance, when comparing the PDE5 inhibitor UK-357903 to the ACE inhibitor enalapril in SHR, the former was effective on day 1 only, while enalapril did not lose efficacy over multiple days.¹¹⁸ Nevertheless, the effects of UK-357903 on vascular conductance and plasma cGMP levels remained present. In contrast, Yaguas et al¹¹⁹ observed blood pressure-lowering effects of sildenafil in SHR after 2 months of treatment only, and this effect remained present during continued treatment up to 6 months. These data imply that there may be some resistance to PDE5 inhibition in the vasculature, especially on the short-term. Whether this is due to feedback via upregulation of PDE1, or any adaptation of downstream signaling, needs to be further addressed. It is worthy to mention that despite its mild effect on blood pressure, PDE5 inhibition exerts protective effects on endothelial cells and VSMC, by increasing NO bioavailability and reducing oxidative stress.^{119,120} For these reasons, PDE5 inhibition is currently used in pulmonary hypertension, in which also PDE1 inhibition has shown promise.¹²¹

Effects in the aging vasculature might be of particular interest for PDE1 and 5 inhibitors. Vascular aging is a leading factor for hypertension development. VSMC from accelerated aging mice with increased blood pressure and human senescent VSMC showed elevated level of PDE1A, PDE1C, and PDE5 expression, and human genetic studies confirmed an association between PDE1A and diastolic blood pressure.^{79,80,122} These observations warrant the exploration of chronic PDE1 inhibition in models of aging.

Protein Kinase G α Activators

In conduit vessels, NO is most relevant for relaxation, while in resistance vessels EDH is prominent. This makes EDH an attractive target for the treatment of hypertension. NO-mediated relaxation depends on PKG type I in VSMC. The *PKGI* gene expresses as 2 separate isoforms (α and β), which are splice variants of the same gene and differ only in sequence of their N-terminal leucine zipper interaction domain.¹²³ They occur as homodimers, and their leucine zipper domains, apart from holding the monomers together, mediate PKG binding to specific substrates. Upon binding of cGMP, auto-inhibitory domains disinhibit phosphorylation activity of the PKGI catalytic region, thus phosphorylation-activating VASP (Figure 5).

EDH-mediated relaxant pathways display great diversity, and among its stimulators are *S*-nitrosothiols and H_2O_2 .^{124,125} Interestingly, through oxidization, H_2O_2 is capable of activating PKGI α in a cGMP-independent manner, inducing the formation of a disulfide bond between the cysteine 42 (C42) residues of 2 adjacent chains in PKGI α homodimers (Figure 5).¹²⁶ The linked PKGI α homodimers phosphorylate large-conductance Ca^{2+} -dependent K^+ (BK_{Ca}) channels, thus leading to hyperpolarization. By screening a large set of electrophilic small molecules, Burgoyne et al¹²⁶ discovered a PKGI α activator, G1.¹²⁷ G1 relaxed arteries to the same degree as cinaciguat, yet without affecting mean arterial pressure in vivo, due to a compensatory heart rate increase. In angiotensin II-infused mice, G1 did lower mean arterial pressure, although the effect waned off gradually. This is reminiscent of the tolerance phenomenon and is suggestive for counterregulatory mechanisms like inactivation of oxidized PKGI α by thioredoxin. In a subsequent study, the same investigators reported that resveratrol, normally considered an antioxidant, was also capable of inducing PKGI α oxidation.¹²⁸ Consequently, like G1, it relaxed pre-constricted arteries and lowered blood pressure in the angiotensin II-infused mice. Stanley et al¹²⁹ reported that the enzyme indoleamine 2,3-dioxygenase 1 in the presence of H_2O_2 generates yet another PKGI α activator, (2*S*,3*aR*,8*aR*)-3*a*-hydroperoxy-1,2,3,3*a*,8,8*a*-hexahydropyrrolo[2,3-*b*]indole-2-carboxylic acid from L-tryptophan. Furthermore, Feelisch et al¹³⁰ observed that nitrite, although generally believed to result in NO-dependent effects, lowered blood pressure by binding to the haem moiety of catalase, thus inhibiting H_2O_2 decomposition and also facilitating PKGI α activation.

Thus, the PKGI α activator field is rapidly evolving. Yet, there still are several caveats. Cys42 may not be the only cysteine residue that can be oxidized to activate: Cys117 seems to be another.¹³¹ Most studies agree on a role for endothelial small- and intermediate conductance Ca^{2+} -dependent K^+ channels in EDH, while activation of BK_{Ca} is less well accepted.¹²⁴ In fact, PKG inhibition with KT5823 blocked the relaxant effects of G1 in mesenteric arteries by only 50%,¹²⁷ while *S*-nitrosothiol-induced EDH did not involve PKGI α activation at all.¹³² Moreover, the sGC activator BAY412272 still evoked vasodilation during sGC inhibition, by activating Na^+ - K^+ -ATPase, implying that even these drugs may

induce EDH.¹²⁵ Clearly, future studies should investigate what non-PKG mechanisms are activated by PKGI α activators, and how sGC activators might exert EDH. Since G1 prevented VASP phosphorylation by the stable cGMP analog 8-Br-cGMP,¹²⁷ it is possible that the cGMP-activated PKGI α -VASP pathway and the oxidized PKGI α - BK_{Ca} pathway are mutually exclusive. If so, we need to know what exactly determines their respective contributions in conduit versus resistance vessels, since PKG occurs at both sites. Ultimately, this will tell us to what degree PKGI α activator truly would be universal vasodilators.

Summary and Perspectives

Currently, no antihypertensive drugs that are directed at improvement of NO—cGMP signaling are in clinical use. To predict which approach is most likely to succeed, a number of aspects needs to be considered.

First, LOX and XO inhibition do not appear to be an option due to the promiscuous behavior towards substrates, leading to formation of substances that both oppose and support vasodilation through NO. Myeloperoxidase and vascular peroxidase 1 appear to be more promising targets, but clinically applicable inhibitors have not been developed yet. NADPH oxidase has had overwhelming attention the past 3 decades, but disappointingly, no clinical drugs are in sight yet. Thus, oxidases seem to be on a hold.

Mitochondrial compounds are intriguing newcomers. There is a profound interaction between NO and mitochondria. Although this interaction remains to be further evaluated, Nrf2 stimulators are inappropriate in hypertension since they activate the RAS, whereas compounds that affect nutrient sensing and the electron transfer chain, for example, modified 6-chromanols such as SUL compounds, are interesting to further explore.

Much closer to the clinic are the compounds that affect the enzymes of the NO-cGMP signaling cascade, sGC, PDE, and PKG, through a direct allosteric interaction. Still far from the clinic are compounds that facilitate PKGI α homodimerization. In addition, they will lead to hyperpolarization of cells rather than specific myosin-actin rearrangement through VASP, thus missing the specific, beneficial cGMP effects. PDE5 inhibition is a clinically feasible strategy, but does not appear to find its way to systemic hypertension. After initial fear for dangerous side effect in several cardiovascular conditions by the end of the 1990s, studies in patients with hypertension were started with a 15-year delay, but the last publication was released more than 10 years ago.¹³³ PDE1 inhibition is an attractive novel option since it very specifically targets the cGMP pool in VSMC. Of note, the specific PDE1 inhibitor ITI-214 is well-tolerated by humans and is in a phase 2 clinical development for neurodegenerative disease.⁴ Since PDE1 appears to have a very specific and differential function in contractile versus proliferating VSMC, PDE1 inhibitors might more specifically exert vascular protection in hypertension in comparison to the other compounds presented here. sGC activators and stimulators are already in clinical use or in clinical development and could be tested in hypertensive disorders on the very short notice. These compounds may combine blood pressure-lowering effects with outcome benefits in cardiovascular diseases.

Sources of Funding

Related to this publication, A.J.M. Roks receives funding and materials from: Stichting Lijf en Leven (Rotterdam, the Netherlands), Project 60; Intracellular Therapies Inc. (New York); Sulfateq B.V. (Groningen, the Netherlands); Topconsortia voor Kennis en Innovatie - Life Science and Health (TKI-LSH) project EMCLSH19013. G. Krenning receives salary from Sulfateq B.V.

Disclosures

None.

References

- GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. *Lancet*. 2016;388:1659–1724. doi: 10.1016/S0140-6736(16)31679-8
- Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extra-cardiac target organ damage in refractory hypertension. *J Hypertens*. 2001;19:2063–2070. doi: 10.1097/00004872-200111000-00018
- Mergia E, Stegbauer J. Role of phosphodiesterase 5 and cyclic GMP in hypertension. *Curr Hypertens Rep*. 2016;18:39. doi: 10.1007/s11906-016-0646-5
- Golshiri K, Ataei Ataabadi E, Portilla Fernandez EC, Jan Danser AH, Roks AJM. The importance of the nitric oxide-cgmp pathway in age-related cardiovascular disease: focus on phosphodiesterase-1 and soluble guanylate cyclase. *Basic Clin Pharmacol Toxicol*. 2020;127:67–80. doi: 10.1111/bcpt.13319
- Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. *J Hypertens*. 2015;33:1128–1136. doi: 10.1097/HJH.0000000000000587
- Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat Rev Drug Discov*. 2008;7:156–167. doi: 10.1038/nrd2466
- Bailey JC, Feelisch M, Horowitz JD, Frenneaux MP, Madhani M. Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation. *Pharmacol Ther*. 2014;144:303–320. doi: 10.1016/j.pharmthera.2014.06.009
- Schäfer A, Burkhardt M, Vollkommer T, Bauersachs J, Münzel T, Walter U, Smolenski A. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. *Biochem Pharmacol*. 2003;65:397–405. doi: 10.1016/s0006-2952(02)01523-x
- Münzel T, Daiber A, Gori T. More answers to the still unresolved question of nitrate tolerance. *Eur Heart J*. 2013;34:2666–2673. doi: 10.1093/eurheartj/ehz249
- Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T. Targeting vascular (endothelial) dysfunction. *Br J Pharmacol*. 2017;174:1591–1619. doi: 10.1111/bph.13517
- Münzel T, Schmidt FP, Steven S, Herzog J, Daiber A, Sørensen M. Environmental noise and the cardiovascular system. *J Am Coll Cardiol*. 2018;71:688–697. doi: 10.1016/j.jacc.2017.12.015
- Fetterman JL, Weisbrod RM, Feng B, Bastin R, Tuttle ST, Holbrook M, Baker G, Robertson RM, Conklin DJ, Bhatnagar A, et al. Flavorings in tobacco products induce endothelial cell dysfunction. *Arterioscler Thromb Vasc Biol*. 2018;38:1607–1615. doi: 10.1161/ATVBAHA.118.311156
- Wölkart G, Kollau A, Stessel H, Russwurm M, Koesling D, Schrammel A, Schmidt K, Mayer B. Effects of flavoring compounds used in electronic cigarette refill liquids on endothelial and vascular function. *PLoS One*. 2019;14:e0222152. doi: 10.1371/journal.pone.0222152
- Anderson C, Majeste A, Hanus J, Wang S. E-Cigarette aerosol exposure induces reactive oxygen species, DNA damage, and cell death in vascular endothelial cells. *Toxicol Sci*. 2016;154:332–340. doi: 10.1093/toxsci/kfw166
- Putzhammer R, Doppler C, Jakschitz T, Heinz K, Förste J, Danzl K, Messner B, Bernhard D. Vapours of US and EU market leader electronic cigarette brands and liquids are cytotoxic for Human vascular endothelial cells. *PLoS One*. 2016;11:e0157337. doi: 10.1371/journal.pone.0157337
- D’Ruiz CD, Graff DW, Yan XS. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. *BMC Public Health*. 2015;15:991. doi: 10.1186/s12889-015-2349-2
- Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, Terentes-Printzios D, Georgakopoulos C, Pietri P, Stefanadis C, Tousoulis D. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. *J Am Coll Cardiol*. 2016;67:2802–2803. doi: 10.1016/j.jacc.2016.03.569
- Kuntic M, Oelze M, Steven S, Kröllner-Schön S, Stamm P, Kalinovic S, Frenis K, Vujacic-Mirski K, Bayo Jimenez MT, Kvandova M, et al. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). *Eur Heart J*. 2020;41:2472–2483. doi: 10.1093/eurheartj/ehz772
- Carnevale R, Sciarretta S, Violi F, Nocella C, Loffredo L, Perri L, Peruzzi M, Marullo AG, De Falco E, Chimenti I, et al. Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function. *Chest*. 2016;150:606–612. doi: 10.1016/j.chest.2016.04.012
- Münzel T, Daiber A, Steven S, Tran LP, Ullmann E, Kossmann S, Schmidt FP, Oelze M, Xia N, Li H, et al. Effects of noise on vascular function, oxidative stress, and inflammation: mechanistic insight from studies in mice. *Eur Heart J*. 2017;38:2838–2849. doi: 10.1093/eurheartj/ehx081
- Mirmiran P, Houshialsadat Z, Gaeini Z, Bahadoran Z, Azizi F. Functional properties of beetroot (*Beta vulgaris*) in management of cardio-metabolic diseases. *Nutr Metab (Lond)*. 2020;17:3. doi: 10.1186/s12986-019-0421-0
- Brown DI, Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. *Circ Res*. 2015;116:531–549. doi: 10.1161/CIRCRESAHA.116.303584
- Brandes RP, Weissmann N, Schröder K. Redox-mediated signal transduction by cardiovascular Nox NADPH oxidases. *J Mol Cell Cardiol*. 2014;73:70–79. doi: 10.1016/j.yjmcc.2014.02.006
- Griendling KK, Touyz RM, Zweier JL, Dikalov S, Chilian W, Chen YR, Harrison DG, Bhatnagar A; American Heart Association Council on Basic Cardiovascular Sciences. Measurement of reactive oxygen species, reactive nitrogen species, and redox-dependent signaling in the cardiovascular system: a scientific statement from the American Heart Association. *Circ Res*. 2016;119:e39–e75. doi: 10.1161/RES.0000000000000110
- Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. *Mol Cell Endocrinol*. 2009;302:148–158. doi: 10.1016/j.mce.2008.11.003
- Montezano AC, Touyz RM. Reactive oxygen species and endothelial function—role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. *Basic Clin Pharmacol Toxicol*. 2012;110:87–94. doi: 10.1111/j.1742-7843.2011.00785.x
- Wenzel P, Kossmann S, Münzel T, Daiber A. Redox regulation of cardiovascular inflammation - Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species. *Free Radic Biol Med*. 2017;109:48–60. doi: 10.1016/j.freeradbiomed.2017.01.027
- Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. *Redox Rep*. 2010;15:50–63. doi: 10.1179/174329210X12650506623401
- Montezano AC, Touyz RM. Molecular mechanisms of hypertension—reactive oxygen species and antioxidants: a basic science update for the clinician. *Can J Cardiol*. 2012;28:288–295. doi: 10.1016/j.cjca.2012.01.017
- Altenhöfer S, Radermacher KA, Kleikers PW, Winkler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. *Antioxid Redox Signal*. 2015;23:406–427. doi: 10.1089/ars.2013.5814
- Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, Mahiout Z, Jansen-Dürr P, Knaus UG, Doroshow J, et al. Pharmacological characterization of the seven human NOX isoforms and their inhibitors. *Redox Biol*. 2019;26:101272. doi: 10.1016/j.redox.2019.101272
- Teixeira G, Szyndralewicz C, Molango S, Carnesecchi S, Heitz F, Wiesel P, Wood JM. Therapeutic potential of NADPH oxidase ¼ inhibitors. *Br J Pharmacol*. 2017;174:1647–1669. doi: 10.1111/bph.13532
- Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. *Vascul Pharmacol*. 2012;56:216–231. doi: 10.1016/j.vph.2012.02.012
- Wang X, Elksnis A, Wikström P, Walum E, Welsh N, Carlsson PO. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro. *PLoS One*. 2018;13:e0204271. doi: 10.1371/journal.pone.0204271
- Hirano K, Chen WS, Chueng AL, Dunne AA, Seredenina T, Filippova A, Ramachandran S, Bridges A, Chaudry L, Pettman G, et al. Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. *Antioxid Redox Signal*. 2015;23:358–374. doi: 10.1089/ars.2014.6202

36. Barton M, Meyer MR, Prossnitz ER. Nox1 downregulators: a new class of therapeutics. *Steroids*. 2019;152:108494. doi: 10.1016/j.steroids.2019.108494
37. Meyer MR, Fredette NC, Daniel C, Sharma G, Amann K, Arterburn JB, Barton M, Prossnitz ER. Obligatory role for GPER in cardiovascular aging and disease. *Sci Signal*. 2016;9:ra105. doi: 10.1126/scisignal.aag0240
38. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev*. 2006;58:87–114. doi: 10.1124/pr.58.1.6
39. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. *Proc Natl Acad Sci U S A*. 2004;101:13683–13688. doi: 10.1073/pnas.0402927101
40. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. *Hypertens Res*. 2014;37:919–925. doi: 10.1038/hr.2014.107
41. Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, Feig DI. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. *J Am Heart Assoc*. 2017;6:e006683. doi: 10.1161/JAHA.117.006683
42. Shirakura T, Nomura J, Matsui C, Kobayashi T, Tamura M, Masuzaki H. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats. *Naunyn Schmiedebergs Arch Pharmacol*. 2016;389:831–838. doi: 10.1007/s00210-016-1239-1
43. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. *N Engl J Med*. 2018;378:1200–1210. doi: 10.1056/NEJMoa1710895
44. Coffey MJ, Natarajan R, Chumley PH, Coles B, Thimmalapura PR, Nowell M, Kühn H, Lewis MJ, Freeman BA, O'Donnell VB. Catalytic consumption of nitric oxide by 12/15-lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. *Proc Natl Acad Sci U S A*. 2001;98:8006–8011. doi: 10.1073/pnas.141136098
45. Aggarwal NT, Chawengsub Y, Gauthier KM, Viita H, Yla-Herttuala S, Campbell WB. Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. *Hypertension*. 2008;51:246–251. doi: 10.1161/HYPERTENSIONAHA.107.104125
46. Aggarwal NT, Gauthier KM, Campbell WB. 15-Lipoxygenase metabolites contribute to age-related reduction in acetylcholine-induced hypotension in rabbits. *Am J Physiol Heart Circ Physiol*. 2008;295:H89–H96. doi: 10.1152/ajpheart.00054.2008
47. Abu-Soud HM, Hazen SL. Nitric oxide modulates the catalytic activity of myeloperoxidase. *J Biol Chem*. 2000;275:5425–5430. doi: 10.1074/jbc.275.8.5425
48. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Luscis AJ, Nauseef WM, White CR, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. *Science*. 2002;296:2391–2394. doi: 10.1126/science.1106830
49. Zhang C, Patel R, Eiserich JP, Zhou F, Kelpke S, Ma W, Parks DA, Darley-Usmar V, White CR. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. *Am J Physiol Heart Circ Physiol*. 2001;281:H1469–H1475. doi: 10.1152/ajpheart.2001.281.4.H1469
50. Zhang C, Reiter C, Eiserich JP, Boersma B, Parks DA, Beckman JS, Barnes S, Kirk M, Baldus S, Darley-Usmar VM, et al. L-arginine chlorination products inhibit endothelial nitric oxide production. *J Biol Chem*. 2001;276:27159–27165. doi: 10.1074/jbc.M100191200
51. Bautista-Nino PK, Portilla-Fernandez E, Vaughan DE, Danser AH, Roks AJ. DNA damage: a main determinant of vascular aging. *Int J Mol Sci*. 2016;17:e748. doi: 10.3390/ijms17050748
52. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, et al; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med*. 2013;369:2492–2503. doi: 10.1056/NEJMoa1306033
53. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b–4 CKD. *Am J Nephrol*. 2011;33:469–476. doi: 10.1159/000327599
54. Zhao S, Ghosh A, Lo CS, Chenier I, Scholey JW, Filep JG, Ingelfinger JR, Zhang SL, Chan JSD. Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice. *Endocrinology*. 2018;159:836–852. doi: 10.1210/en.2017-00752
55. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest*. 2003;111:1201–1209. doi: 10.1172/JCI14172
56. Liu Z, Liu Y, Xu Q, Peng H, Tang Y, Yang T, Yu Z, Cheng G, Zhang G, Shi R. Critical role of vascular peroxidase 1 in regulating endothelial nitric oxide synthase. *Redox Biol*. 2017;12:226–232. doi: 10.1016/j.redox.2017.02.022
57. Hajmoussa G, Vogelaar P, Brouwer LA, van der Graaf AC, Henning RH, Krenning G. The 6-chromanol derivate SUL-109 enables prolonged hypothermic storage of adipose tissue-derived stem cells. *Biomaterials*. 2017;119:43–52. doi: 10.1016/j.biomaterials.2016.12.008
58. Lambooy SPH, Bidarkosh A, Nakladal D, van Buiten A, Girgis RAT, van der Graaf AC, Wiedenmann TJ, Koster RA, Vogelaar P, Buikema H, et al. The novel compound Sul-121 preserves endothelial function and inhibits progression of kidney damage in type 2 diabetes mellitus in mice. *Sci Rep*. 2017;7:11165. doi: 10.1038/s41598-017-11582-6
59. Vogelaar PC, Roorda M, de Vrij EL, Houwertjes MC, Goris M, Bouma H, van der Graaf AC, Krenning G, Henning RH. The 6-hydroxychromanol derivative SUL-109 ameliorates renal injury after deep hypothermia and rewarming in rats. *Nephrol Dial Transplant*. 2018;33:2128–2138. doi: 10.1093/ndt/gfy080
60. Fridovich I. Superoxide anion radical (O₂⁻), superoxide dismutases, and related matters. *J Biol Chem*. 1997;272:18515–18517. doi: 10.1074/jbc.272.30.18515
61. Yang Z, Zhang A, Altura BT, Altura BM. Hydrogen peroxide-induced endothelium-dependent relaxation of rat aorta involvement of Ca²⁺ and other cellular metabolites. *Gen Pharmacol*. 1999;33:325–336. doi: 10.1016/s0306-3623(99)00019-1
62. Zhou X, Yuan D, Wang M, He P. H₂O₂-induced endothelial NO production contributes to vascular cell apoptosis and increased permeability in rat venules. *Am J Physiol Heart Circ Physiol*. 2013;304:H82–H93. doi: 10.1152/ajpheart.00300.2012
63. Maassen H, Hendriks KDW, Venema LH, Henning RH, Hofker SH, van Goor H, Leuvenink HGD, Coester AM. Hydrogen sulphide-induced hypometabolism in human-sized porcine kidneys. *PLoS One*. 2019;14:e0225152. doi: 10.1371/journal.pone.0225152
64. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R, Tan CH, Moore PK. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. *Circulation*. 2008;117:2351–2360. doi: 10.1161/CIRCULATIONAHA.107.753467
65. Nakladal D, Buikema H, Romero AR, Lambooy SPH, Bouma J, Krenning G, Vogelaar P, van der Graaf AC, Groves MR, Kyselovic J, et al. The @-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α1-adrenoceptor. *Sci Rep*. 2019;9:13. doi: 10.1038/s41598-018-36788-0
66. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cochemé HM, Murphy MP, Dominiczak AF. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. *Hypertension*. 2009;54:322–328. doi: 10.1161/HYPERTENSIONAHA.109.130351
67. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. *Circ Res*. 2010;107:106–116. doi: 10.1161/CIRCRESAHA.109.214601
68. Eisner V, Picard M, Hajnóczky G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. *Nat Cell Biol*. 2018;20:755–765. doi: 10.1038/s41556-018-0133-0
69. Eirin A, Hedayat AF, Ferguson CM, Textor SC, Lerman A, Lerman LO. Mitoprotection preserves the renal vasculature in porcine metabolic syndrome. *Exp Physiol*. 2018;103:1020–1029. doi: 10.1113/EP086988
70. Yuan F, Hedayat AF, Ferguson CM, Lerman A, Lerman LO, Eirin A. Mitoprotection attenuates myocardial vascular impairment in porcine metabolic syndrome. *Am J Physiol Heart Circ Physiol*. 2018;314:H669–H680. doi: 10.1152/ajpheart.00431.2017
71. Liu X, Tan H, Liu X, Wu Q. Correlation between the expression of Drp1 in vascular endothelial cells and inflammatory factors in hypertension rats. *Exp Ther Med*. 2018;15:3892–3898. doi: 10.3892/etm.2018.5899
72. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial

- dysfunction in aging blood vessels. *Circulation*. 2003;108:2000–2006. doi: 10.1161/01.CIR.0000092948.04444.C7
73. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, Mc Donald MM, Humphrey JD, Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. *Hypertension*. 2004;44:935–943. doi: 10.1161/01.HYP.0000146907.82869.f2
 74. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. *Am J Physiol Regul Integr Comp Physiol*. 2005;288:R1057–R1062. doi: 10.1152/ajpregu.00758.2004
 75. Koo BH, Hwang HM, Yi BG, Lim HK, Jeon BH, Hoe KL, Kwon YG, Won MH, Kim YM, Berkowitz DE, et al. Arginase II contributes to the Ca²⁺/CaMKII/eNOS axis by regulating Ca²⁺ concentration between the cytosol and mitochondria in a p32-dependent manner. *J Am Heart Assoc*. 2018;7:e009579. doi: 10.1161/JAHA.118.009579
 76. Pham TN, Bordage S, Pudlo M, Demougeot C, Thai KM, Girard-Thernier C. Cinnamide derivatives as mammalian arginase inhibitors: synthesis, biological evaluation and molecular docking. *Int J Mol Sci*. 2016;17:1656. doi: 10.3390/ijms17101656
 77. Pudlo M, Demougeot C, Girard-Thernier C. Arginase inhibitors: a rational approach over one century. *Med Res Rev*. 2017;37:475–513. doi: 10.1002/med.21419
 78. Lacza Z, Pankotai E, Busija DW. Mitochondrial nitric oxide synthase: current concepts and controversies. *Front Biosci (Landmark Ed)*. 2009;14:4436–4443. doi: 10.2741/3539
 79. Durik M, Kavousi M, van der Pluijm I, Isaacs A, Cheng C, Verdonk K, Loot AE, Oeseburg H, Bhaggoo UM, Leijten F, et al. Nucleotide excision DNA repair is associated with age-related vascular dysfunction. *Circulation*. 2012;126:468–478. doi: 10.1161/CIRCULATIONAHA.112.104380
 80. Bautista Niño PK, Durik M, Danser AH, de Vries R, Musterd-Bhaggoo UM, Meima ME, Kavousi M, Ghanbari M, Hoeijmakers JH, O'Donnell CJ, et al. Phosphodiesterase 1 regulation is a key mechanism in vascular aging. *Clin Sci (Lond)*. 2015;129:1061–1075. doi: 10.1042/CS20140753
 81. Wu H, van Thiel BS, Bautista-Niño PK, Reiling E, Durik M, Leijten FPJ, Ridwan Y, Brandt RMC, van Steeg H, Dollé MET, et al. Dietary restriction but not angiotensin II type 1 receptor blockade improves DNA damage-related vasodilator dysfunction in rapidly aging Erc1Δ/Δ mice. *Clin Sci (Lond)*. 2017;131:1941–1953. doi: 10.1042/CS20170026
 82. Vermeij WP, Dollé ME, Reiling E, Jaarsma D, Payan-Gomez C, Bombardieri CR, Wu H, Roks AJ, Botter SM, van der Eerden BC, et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice. *Nature*. 2016;537:427–431. doi: 10.1038/nature19329
 83. Garinis GA, Uittenboogaard LM, Stachelscheid H, Fousteri M, van Ijcken W, Breit TM, van Steeg H, Mullenders LH, van der Horst GT, Brüning JC, et al. Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity. *Nat Cell Biol*. 2009;11:604–615. doi: 10.1038/ncb1866
 84. Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP. Soluble guanylate cyclase stimulators and activators [published online ahead of print January 29, 2019]. *Handb Exp Pharmacol*. 2019. doi: 10.1007/164_2018_197
 85. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowski K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. *Br J Pharmacol*. 2002;136:773–783. doi: 10.1038/sj.bjp.0704778
 86. Mülsch A, Bauersachs J, Schäfer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. *Br J Pharmacol*. 1997;120:681–689. doi: 10.1038/sj.bjp.0700982
 87. Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. *Br J Pharmacol*. 1999;127:195–203. doi: 10.1038/sj.bjp.0702495
 88. Stasch JP, Alonso-Alija C, Apeler H, Dembowski K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. *Br J Pharmacol*. 2002;135:333–343. doi: 10.1038/sj.bjp.0704484
 89. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muentner K, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. *ChemMedChem*. 2009;4:853–865. doi: 10.1002/cmdc.200900014
 90. Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. *J Med Chem*. 2017;60:5146–5161. doi: 10.1021/acs.jmedchem.7b00449
 91. Rothermund L, Friebe A, Paul M, Koesling D, Kreutz R. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. *Br J Pharmacol*. 2000;130:205–208. doi: 10.1038/sj.bjp.0703320
 92. Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, et al. Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease. *J Pharmacol Exp Ther*. 2018;365:664–675. doi: 10.1124/jpet.117.247429
 93. Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, Masferrer JL. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. *Am J Physiol Renal Physiol*. 2020;318:F148–F159. doi: 10.1152/ajprenal.00247.2019
 94. Schindler U, Strobel H, Schönafinger K, Linz W, Löhn M, Martorana PA, Rütten H, Schindler PW, Busch AE, Sohn M, et al. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. *Mol Pharmacol*. 2006;69:1260–1268. doi: 10.1124/mol.105.018747
 95. Stasch JP, Dembowski K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. *Br J Pharmacol*. 2002;135:344–355. doi: 10.1038/sj.bjp.0704483
 96. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, Kato J, Asada Y, Stasch JP, Kitamura K. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. *Hypertens Res*. 2009;32:597–603. doi: 10.1038/hr.2009.64
 97. Hoffmann LS, Etzrodt J, Willkomm L, Sanyal A, Scheja L, Fischer AWC, Stasch JP, Bloch W, Friebe A, Heeren J, et al. Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. *Nat Commun*. 2015;6:7235. doi: 10.1038/ncomms8235
 98. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hücke A, Hocher B, Stasch JP. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. *PLoS One*. 2011;6:e21853. doi: 10.1371/journal.pone.0021853
 99. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, Geschka S, Relle K, Hocher B, Stasch JP. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. *J Hypertens*. 2010;28:1666–1675. doi: 10.1097/HJH.0b013e32833b558c
 100. Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, Rütten H, Amann K. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. *Kidney Blood Press Res*. 2007;30:224–233. doi: 10.1159/000104091
 101. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, et al. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. *Front Pharmacol*. 2012;3:128. doi: 10.3389/fphar.2012.00128
 102. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2020;382:1883–1893. doi: 10.1056/NEJMoa1915928
 103. Erdmann E, Semigran MJ, Nieminen MS, Gheorghide M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. *Eur Heart J*. 2013;34:57–67. doi: 10.1093/eurheartj/ehs196
 104. Gheorghide M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. *Eur J Heart Fail*. 2012;14:1056–1066. doi: 10.1093/eurjhf/hfs093

105. Breitenstein S, Roessig L, Sandner P, Lewis KS. Novel sGC stimulators and sGC activators for the treatment of heart failure. *Handb Exp Pharmacol*. 2017;243:225–247. doi: 10.1007/164_2016_100
106. Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT. A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects. *Clin Pharmacol Drug Dev*. 2019;8:564–575. doi: 10.1002/epdd.627
107. Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL III, Michelson AD, et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. *Diabetologia*. 2020;63:733–743. doi: 10.1007/s00125-019-05062-x
108. Tousoulis D, Androulakis E, Papageorgiou N, Stefanadis C. Novel therapeutic strategies in the management of arterial hypertension. *Pharmacol Ther*. 2012;135:168–175. doi: 10.1016/j.pharmthera.2012.05.004
109. Laursen M, Beck L, Kehler J, Christoffersen CT, Bundgaard C, Mogensen S, Mow TJ, Pinilla E, Knudsen JS, Hedegaard ER, et al. Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. *Br J Pharmacol*. 2017;174:2563–2575. doi: 10.1111/bph.13868
110. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. *Circ Res*. 2002;90:151–157. doi: 10.1161/hh0202.104108
111. Yan C. Cyclic nucleotide phosphodiesterase 1 and vascular aging. *Clin Sci (Lond)*. 2015;129:1077–1081. doi: 10.1042/CS20150605
112. Wang X, Yamada S, LaRivière WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, et al. Generation and phenotypic characterization of Pde1a mutant mice. *PLoS One*. 2017;12:e0181087. doi: 10.1371/journal.pone.0181087
113. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. *Am J Cardiol*. 2005;96(12B):42M–46M. doi: 10.1016/j.amjcard.2005.07.011
114. Manuel T, Sema HS, Evanthia M, Sebastian AP, Guang Y, Lydia H, Katharina G, Henning H, Lars CR, Johannes S. Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction. *Am J Physiol Renal Physiol*. 2017;312:F474–F481. doi: 10.1152/ajprenal.00376.2016
115. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. *Hypertension*. 2005;46:932–936. doi: 10.1161/01.HYP.0000182154.61862.52
116. Fernanda RG, Victor VL, Fernando SC, Rita CT, Webb RC. Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats. *Hypertension*. 2011;57:655–663. doi: 10.1161/HYPERTENSIONAHA.110.164327
117. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. *J Mol Cell Cardiol*. 2005;38:175–184. doi: 10.1016/j.yjmcc.2004.10.013
118. Gardiner SM, March JE, Kemp PA, Ballard SA, Hawkeswood E, Hughes B, Bennett T. Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. *Br J Pharmacol*. 2004;141:114–122. doi: 10.1038/sj.bjp.0705581
119. Yaguas K, Bautista R, Quiroz Y, Ferrebuz A, Pons H, Franco M, Vaziri ND, Rodriguez-Iturbe B. Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension. *Am J Nephrol*. 2010;31:283–291. doi: 10.1159/000279307
120. Leal MAS, Aires R, Pandolfi T, Marques VB, Campagnaro BP, Pereira TMC, Meyrelles SS, Campos-Toimil M, Vasquez EC. Sildenafil reduces aortic endothelial dysfunction and structural damage in spontaneously hypertensive rats: role of NO, NADPH and COX-1 pathways. *Vascul Pharmacol*. 2020;124:106601. doi: 10.1016/j.vph.2019.106601
121. Patrick C, Zhongjie S. Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. *Hypertension*. 2013;61:585–592. doi: 10.1161/HYPERTENSIONAHA.111.00676
122. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. *Am J Hum Genet*. 2014;94:349–360. doi: 10.1016/j.ajhg.2013.12.016
123. Kong Q, Blanton RM. Protein kinase G I and heart failure: shifting focus from vascular unloading to direct myocardial antiremodeling effects. *Circ Heart Fail*. 2013;6:1268–1283. doi: 10.1161/CIRCHEARTFAILURE.113.000575
124. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. *Trends Pharmacol Sci*. 2002;23:374–380. doi: 10.1016/s0165-6147(02)02050-3
125. Batenburg WW, Kappers MH, Eikmann MJ, Ramzan SN, de Vries R, Danser AH. Light-induced vs. bradykinin-induced relaxation of coronary arteries: do S-nitrosothiols act as endothelium-derived hyperpolarizing factors? *J Hypertens*. 2009;27:1631–1640. doi: 10.1097/HJH.0b013e3283283b54
126. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schröder E, Browning DD, Eaton P. Cysteine redox sensor in PKG1a enables oxidant-induced activation. *Science*. 2007;317:1393–1397. doi: 10.1126/science.1144318
127. Burgoyne JR, Prisyazhna O, Richards DA, Eaton P. Proof of principle for a novel class of antihypertensives that target the oxidative activation of PKG 1α (Protein Kinase G 1α). *Hypertension*. 2017;70:577–586. doi: 10.1161/HYPERTENSIONAHA.117.09670
128. Prisyazhna O, Wollhuter K, Switzer C, Santos C, Yang X, Lynham S, Shah AM, Eaton P, Burgoyne JR. Blood pressure-lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of cGMP-dependent protein kinase. *Circulation*. 2019;140:126–137. doi: 10.1161/CIRCULATIONAHA.118.037398
129. Stanley CP, Maghazl GJ, Ayer A, Talib J, Giltrap AM, Shengule S, Wollhuter K, Wang Y, Chadha P, Suarna C, et al. Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation. *Nature*. 2019;566:548–552. doi: 10.1038/s41586-019-0947-3
130. Feelisch M, Akaïke T, Griffiths K, Ida T, Prisyazhna O, Goodwin JJ, Gollop ND, Fernandez BO, Minnion M, Cortese-Krott MM, et al. Long-lasting blood pressure lowering effects of nitrite are NO-independent and mediated by hydrogen peroxide, persulfides, and oxidation of protein kinase G1α redox signalling. *Cardiovasc Res*. 2020;116:51–62. doi: 10.1093/cvr/cvz202
131. Sheehe JL, Bonev AD, Schmoker AM, Ballif BA, Nelson MT, Moon TM, Dostmann WR. Oxidation of cysteine 117 stimulates constitutive activation of the type 1α cGMP-dependent protein kinase. *J Biol Chem*. 2018;293:16791–16802. doi: 10.1074/jbc.RA118.004363
132. Bautista-Niño PK, van der Stel M, Batenburg WW, de Vries R, Roks AJM, Danser AHJ. Endothelium-derived hyperpolarizing factor and protein kinase G 1α activation: H2O2 versus S-nitrosothiols. *Eur J Pharmacol*. 2018;827:112–116. doi: 10.1016/j.ejphar.2018.03.019
133. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. NO-independent regulatory site on soluble guanylate cyclase. *Nature*. 2001;410:212–215. doi: 10.1038/35065611
134. Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. *J Sex Med*. 2013;10:1268–1277. doi: 10.1111/jsm.12095
135. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2013;369:330–340. doi: 10.1056/NEJMoa1209655
136. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, et al; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2013;369:319–329. doi: 10.1056/NEJMoa1209657
137. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in the ArT failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. *Eur Heart J*. 2017;38:1119–1127. doi: 10.1093/eurheartj/ehw593
138. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. *Vascul Pharmacol*. 2006;45:154–162. doi: 10.1016/j.vph.2006.05.002
139. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, Mittleman RS, Profy AT, Seferovic JP, Reasner D, et al. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart

- failure with preserved ejection fraction (CAPACITY HFpEF). *Am Heart J*. 2020;222:183–190. doi: 10.1016/j.ahj.2020.01.009
140. van Eickels M, Wassmann S, Schäfer A, et al. Role of the sGC activator ataciguat sodium (HMR1766) in cardiovascular disease. *BMC Pharmacol*. 2007;7:S4. doi: 10.1186/1471-2210-7-S1-S4
141. Tawa M, Furukawa T, Tongu H, Sugihara M, Taguwa S, Yamanaka M, Yano Y, Matsumori H, Kitada R, Sawano T, et al. Stimulation of nitric oxide-sensitive soluble guanylate cyclase in monocrotaline-induced pulmonary hypertensive rats. *Life Sci*. 2018;203:203–209. doi: 10.1016/j.lfs.2018.04.045
142. Pankey EA, Bhartiya M, Badejo AM Jr, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. *Am J Physiol Heart Circ Physiol*. 2011;300:H792–H802. doi: 10.1152/ajpheart.00953.2010
143. Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, et al. A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 Rat. *J Pharmacol Exp Ther*. 2016;356:712–719. doi: 10.1124/jpet.115.230706